

DAFTAR PUSTAKA

1. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. *Crit Care Med.* 2021;49(11):1–81. doi:10.1097/CCM.0000000000005337
2. Gatewood MO, Wemple M, Greco S, Kritek PA, Durvasula R. A quality improvement project to improve early sepsis care in the emergency department. *BMJ Qual Saf.* 2015;24(12):787–95. doi:10.1136/bmjqs-2014-003552
3. World Health Organization. Global Report on the Epidemiology and Burden of Sepsis: Current Evidence, Identifying Gaps and Future Directions. 1st ed. Geneva: World Health Organization; 2020. 56 p.
4. Kabi A, Mohanty A, Kumar S, Singh V, Jha M, Gupta P. Clinical Spectrum and Risk Factors for Hospital-Acquired Septicemia in A Tertiary Care Centre of North-East India. *J Fam Med Prim Care.* 2020;9(8):1–8. doi:10.4103/jfmpe.jfmpe_469_20
5. Gyawali B, Ramakrishna K, Dhamoon AS. Sepsis: The evolution in definition, pathophysiology, and management. *SAGE Open Med.* 2019;7(1):1–13. doi:10.1177/2050312119835043
6. Gusriadi B, Salam SH, Hisbullah H, Arif SK, Rum M, Palinrunji AS. The Association of Cumulative Fluid Balance and Sepsis Patient Mortality During Treatment in the Intensive Care Unit. *Nusant Med Sci J.* 2022;7(2):88–97. doi:10.20956/nmsj.v7i2.20229
7. Hasanah U, Handayani I, Nurulita A. Analysis of C-reactive protein/albumin ratio as a predictor of mortality in sepsis patients. *J Kedokt Dan Kesehat Indones.* 2023;14(1):16–23. doi:10.20885/JKKI.Vol14.Iss1.art4
8. Rohman AF, Radji M, Rianti A, Rachman A. Evaluation of the Use of Antibiotics on Therapy Results of Sepsis Patients in the Intensive Care Unit (ICU) of Fatmawati Hospital, Jakarta. *J Med Chem Sci.* 2024;7(1):262–74.
9. Veralina Y. Evaluasi Penggunaan Antibiotik pada Pasien Sepsis di Ruang ICU (Intensive Care Unit) RSUD Pasaman Barat [Skripsi]. Padang: Universitas Andalas; 2021.
10. Zhou X, Su LX, Zhang JH, Liu DW, Long Y. Rules of anti-infection therapy for sepsis and septic shock. *Chin Med J (Engl).* 2019;132(5):589–96. doi:10.1097/CM9.0000000000000101

11. Seok H, Jeon JH, Park DW. Antimicrobial Therapy and Antimicrobial Stewardship in Sepsis. *Infect Chemother.* 2020;52(1):19. doi:10.3947/ic.2020.52.1.19
12. Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 Update. *Intensive Care Med.* 2018;44(6):925–8. doi:10.1007/s00134-018-5085-0
13. Gai X, Wang Y, Gao D, Ma J, Zhang C, Wang Q. Risk factors for the prognosis of patients with sepsis in intensive care units. *PLOS ONE.* 2022;17(9):1–8. doi:10.1371/journal.pone.0273377
14. Ihsan S, Kartina K, Akib NI. Studi Penggunaan Antibiotik Non Resep Di Apotek Komunitas Kota Kendari. *Media Farm J Ilmu Farm.* 2016;13(2):272. doi:10.12928/mf.v13i2.7778
15. Ishak A, Mazonakis N, Spernovasilis N, Akinosoglou K, Tsioutis C. Bactericidal versus Bacteriostatic Antibacterials: Clinical Significance, Differences and Synergistic Potential in Clinical Practice. *J Antimicrob Chemother.* 2025;80(1):1–17. doi:10.1093/jac/dkae380
16. Kementerian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/MENKES/4722/2021 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Sepsis Pada Anak. Jakarta: Kemenkes RI; 2021. 1–55 p.
17. Frei A, Verderosa AD, Elliott AG, Zuegg J, Blaskovich MAT. Metals to Combat Antimicrobial Resistance. *Nat Rev Chem.* 2023;7(3):202–24. doi:10.1038/s41570-023-00463-4
18. Grada A, Bunick CG. Spectrum of Antibiotic Activity and Its Relevance to the Microbiome. *JAMA Netw Open.* 2021;4(4):1–2. doi:10.1001/jamanetworkopen.2021.5357
19. Kementerian Kesehatan Republik Indonesia. Pedoman Penggunaan Antibiotik di Rumah Sakit. Jakarta: Kemenkes RI; 2011.
20. Maramba-Lazarte CC. Determining Correct Dosing Regimens of Antibiotics Based on the Their Bactericidal Activity. *PIDSP.* 2010;11(2):44–9.
21. Dougherty TJ, Pucci MJ, editors. *Antibiotic Discovery and Development.* Boston, MA: Springer US; 2012. doi:10.1007/978-1-4614-1400-1
22. Anggita D, Nurisyah S, Wiriansya EP. Mekanisme Kerja Antibiotik: Review Article. *UMI Med J.* 2022;7(1):46–58. doi:10.33096/umj.v7i1.149

23. Wang F, Zhou H, Olademehin OP, Kim SJ, Tao P. Insights into Key Interactions between Vancomycin and Bacterial Cell Wall Structures. *ACS Omega*. 2018;3(1):37–45. doi:10.1021/acsomega.7b01483
24. Peloquin CA, Davies GR. The Treatment of Tuberculosis. *Clin Pharmacol Ther*. 2021;110(6):1455–66. doi:10.1002/cpt.2261
25. Spencer AC, Panda SS. DNA Gyrase as a Target for Quinolones. *Biomedicines*. 2023;11(2):371. doi:10.3390/biomedicines11020371
26. Lade H, Kim JS. Bacterial Targets of Antibiotics in Methicillin-Resistant *Staphylococcus aureus*. *Antibiotics*. 2021;10(4):398. doi:10.3390/antibiotics10040398
27. Masripah S, Rosmiati M. Profil Penggunaan Antibiotik pada Pasien Klinik Anak di Rumah Sakit MM Indramayu Periode Januari-Maret 2021. *J Health Sains*. 2021;2(11):1490–504. doi:10.46799/jhs.v2i11.338
28. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Nomor 8 Tahun 2015 tentang Program Pengendalian Resistansi Antimikroba Di Rumah Sakit. Jakarta: Kemenkes RI; 2015.
29. Verraes C, Van Boxtael S, Van Meervenne E, Van Coillie E, Butaye P, Catry B, et al. Antimicrobial Resistance in the Food Chain: A Review. *Int J Environ Res Public Health*. 2013;10(7):2643–69. doi:10.3390/ijerph10072643
30. Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. *AIMS Microbiol*. 2018;4(3):482–501. doi:10.3934/microbiol.2018.3.482
31. Grossman TH. Tetracycline Antibiotics and Resistance. *Cold Spring Harb Perspect Med*. 2016;6(4):1–26. doi:10.1101/cshperspect.a025387
32. RSUD Mohammad Natsir. Pedoman Penggunaan Antibiotik Tahun 2022. Solok: RSUD Mohammad Natsir; 2022. 1–22 p.
33. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801–10. doi:10.1001/jama.2016.0287
34. Rello J, Valenzuela-Sánchez F, Ruiz-Rodríguez M, Moyano S. Sepsis: A Review of Advances in Management. *Adv Ther*. 2017;34(11):2393–411. doi:10.1007/s12325-017-0622-8
35. Yao RQ, Ren C, Zheng LY, Xia ZF, Yao YM. Advances in Immune Monitoring Approaches for Sepsis-Induced Immunosuppression. *Front Immunol*. 2022;13:1–15. doi:10.3389/fimmu.2022.891024

36. Dipiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey LM. Sepsis and Septic Shock. In: Dipiro's Pharmacotherapy: A Pathophysiologic Approach. 12th ed. United States: McGraw-Hill Company; 2023. 2003–2020 p.
37. Reaven MS, Rozario NL, McCarter MSJ, Heffner AC. Incidence and risk factors associated with early death in patients with emergency department septic shock. *Acute Crit Care*. 2022;37(2):193–201. doi:10.4266/acc.2021.00857
38. Wicaksono A, Adisasmata AC, Harijanto E. Frekuensi dan Mortalitas Pasien Sepsis dan Syok Septik di ICU Rumah Sakit Swasta Tipe B, di Tangerang Selatan. *J Epidemiol Kesehat Indones*. 2022;6(1):1–11. doi:10.7454/epidkes.v6i1.6031
39. Dolin HH, Papadimos TJ, Chen X, Pan ZK. Characterization of Pathogenic Sepsis Etiologies and Patient Profiles: A Novel Approach to Triage and Treatment. *Microbiol Insights*. 2019;12(1):1–8. doi:10.1177/1178636118825081
40. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. *Virulence*. 2014;5(1):4–11. doi:10.4161/viru.27372
41. Palavutitotai N, Jitmuang A, Tongsai S, Kiratisin P, Angkasekwinai N. Epidemiology and risk factors of extensively drug-resistant pseudomonas aeruginosa infections. *PLOS ONE*. 2018;13(2):1–13. doi:10.1371/journal.pone.0193431
42. Thaden JT, Li Y, Ruffin F, Maskarinec SA, Hill-Rorie JM, Wanda LC, et al. Increased Costs Associated with Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Bacteria Are Due Primarily to Patients with Hospital-Acquired Infections. *Antimicrob Agents Chemother*. 2017;61(3):1709–16. doi:10.1128/AAC.01709-16
43. Azaria A. Pola Penggunaan Antibiotik Pada Pasien Sepsis Rawat Inap RSUP Dr. M. Djamil Padang tahun 2017 [Skripsi]. Padang: Universitas Andalas; 2018.
44. Hidayati PH, Danial NF, Mulyadi FE, Sodiqah Y, Handayani H. Gambaran Kultur Bakteri dan Sensitivitas Antibiotik pada Pasien Sepsis di Rumah Sakit Ibnu Sina Periode 2019-2022. *Alami J Alauddin Islam Med J*. 2024;8(1):40–8. doi:10.24252/alami.v8i1.43084
45. Mahapatra S, Heffner AC, Atarhi-Dugan. *Septic Shock (Nursing)*. Treasure Island (FL): StatPearls Publishing; 2023.
46. Mahapatra S, Heffner AC. *Septic Shock*. Treasure Island (FL): StatPearls Publishing; 2023.

47. Kementerian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/342/2017 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Sepsis. Jakarta: Kemenkes RI; 2017.
48. Lestari DA, Wijaya V, Kuncoro H. Karakteristik dan Penggunaan Antibiotik Pasien Sepsis di Rumah Sakit Abdul Wahab Sjahranie Periode 2017. *Proceeding Mulawarman Pharm Conf.* 2018;7:1–7. doi:10.25026/mpc.v7i1.283
49. Hidayat F, Setiadi AP, Setiawan E. Kajian Penggunaan Antibiotik pada Neonatus Intensive Care Unit di Sebuah Rumah Sakit Pemerintah di Surabaya. *Indones J Clin Pharm.* 2019;8(1):58–71. doi:10.15416/ijcp.2019.8.1.58
50. Astutik AW, Annisa N, Rusli R, Ibrahim A. Kajian Kesesuaian Pemilihan Antibiotik Empiris pada Pasien Sepsis di Instalasi Rawat Inap RSUD Abdul Wahab Sjahranie Samarinda. *Proceeding Mulawarman Pharm Conf.* 2017;5:38–47. doi:10.25026/mpc.v5i1.219
51. Rumah Sakit Universitas Andalas. *Panduan Praktik Klinis Rumah Sakit Sepsis.* Padang: Rumah Sakit Universitas Andalas; 2022.
52. Rumah Sakit Universitas Andalas. *Panduan Praktik Klinis Rumah Sakit Sepsis Pada Usia Lanjut (≥60 Tahun) Dengan Komorbid.* Padang: Rumah Sakit Universitas Andalas; 2024.
53. Nugraheni AY, Utami MSP, Saputro AY. Evaluasi Ketepatan Antibiotik pada Pasien Sepsis. *Pharmacon J Farm Indones.* 2021;18(2):194–207.
54. Karizki MR, Puspitasari I, Asdie RH. Rasionalitas Penggunaan Antibiotik Empirik dan Definitif pada Pasien Sepsis di Intensive Care Unit RSUP. Dr. Sardjito. *Maj Farm.* 2021;17(3):343–54. doi:10.22146/farmaseutik.v1i1.62045
55. Lakbar I, Einav S, Lalevée N, Martin-Loeches I, Pastene B, Leone M. Interactions between Gender and Sepsis—Implications for the Future. *Microorganisms.* 2023;11(3):1–16. doi:10.3390/microorganisms11030746
56. Angele MK, Pratschke S, Hubbard WJ, Chaudry IH. Gender differences in sepsis: Cardiovascular and Immunological aspects. *Virulence.* 2014;5(1):12–9. doi:10.4161/viru.26982
57. Berkowitz DM, Martin GS. Sepsis and Sex, Can We Look Beyond Our Hormones? *Chest.* 2007;132(6):1725–7. doi:10.1378/chest.07-2001
58. Randolph AG, McCulloh RJ. Pediatric Sepsis: important considerations for diagnosing and managing severe infections in infants, children, and adolescents. *Virulence.* 2014;5(1):179–89. doi:10.4161/viru.27045

59. Vincent JL. The Prevalence of Nosocomial Infection in Intensive Care Units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. *JAMA*. 1995;274(8):639–44. doi:10.1001/jama.1995.03530080055041
60. World Health Organization. Newborn Health [Internet]. 2021 (cited 2026 Feb 11). Available from: https://www.who.int/westernpacific/health-topics/newborn-health#tab=tab_1
61. Dipiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey LM. Geriatrics: Physiology of Aging. In: Dipiro's Pharmacotherapy: A Pathophysiologic Approach. 12th ed. United States: McGraw-Hill Company; 2023. 1–7 p.
62. Dipiro JT, Yee GC, Nolin TD, Ellingrod VL, Posey LM. Pediatrics: General Topics in Pediatric Pharmacotherapy. In: Dipiro's Pharmacotherapy: A Pathophysiologic Approach. 12th ed. United States: McGraw-Hill Company; 2023. 1–13 p.
63. Teshager NW, Amare AT, Tamirat KS. Incidence and predictors of mortality among children admitted to the pediatric intensive care unit at the University of Gondar comprehensive specialised hospital, northwest Ethiopia: a prospective observational cohort study. *BMJ Open*. 2020;10(10):1–7. doi:10.1136/bmjopen-2019-036746
64. Kari KA, Shukeri WFWM, Yaacob NM, Li AY, Zaini RH, Mazlan MZ. Prevalence and Outcome of Sepsis: Mortality and Prolonged Intensive Care Unit Stay among Sepsis Patients Admitted to a Tertiary Centre in Malaysia. *Malays J Med Sci*. 2023;30(6):120–32. doi:10.21315/mjms2023.30.6.12
65. Thingstad AT, Gustad LT, Skei NV, Lydersen S, Sagberg LM. Rehabilitation ward holiday closure and the course of sepsis. *Sykepl Forsk*. 2024;19(96226):1–17. doi:10.4220/Sykepleienf.2024.96226en
66. Rhee C, Dantes R, Epstein L, Murphy DJ, Seymour CW, Iwashyna TJ, et al. Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014. *JAMA*. 2017;318(13):1241–9. doi:10.1001/jama.2017.13836
67. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. *Clin Infect Dis*. 2007;44(2):S27–72. doi:10.1086/511159

68. Vincent JL. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. *JAMA*. 2009;302(21):1–49. doi:10.1001/jama.2009.1754
69. Podschun R, Ullmann U. *Klebsiella* spp. as Nosocomial Pathogens: Epidemiology, Taxonomy, Typing Methods, and Pathogenicity Factors. *Clin Microbiol Rev*. 1998;11(4):589–603. doi:10.1128/CMR.11.4.589
70. Kauffman CA. Fungal Infections in Older Adults. *Clin Infect Dis*. 2001;33(4):550–5. doi:10.1086/322685
71. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clin Infect Dis*. 2020;71(6):1367–76. doi:10.1093/cid/ciz1008
72. Gellatly SL, Hancock REW. *Pseudomonas aeruginosa* : New Insights into Pathogenesis and Host Defenses. *Pathog Dis*. 2013;67(3):159–73. doi:10.1111/2049-632X.12033
73. DrugBank Online. Ceftriaxone [Internet]. 2024 (cited 2026 Jan 30). Available from: <https://go.drugbank.com/drugs/DB01212>
74. Shirin M, Shahidul Islam Md. Ceftriaxone, an Empirical Goldmine: A Systematic Review of Randomized Controlled Trials. *Mathews J Pharm Sci*. 2020;4(1):1–5. doi:10.30654/MJPS.10001
75. Gorgulho A, Cunha F, Alves Branco E, Azevedo A, Almeida F, Duro R, et al. Appropriateness of Empirical Prescriptions of Ceftriaxone and Identification of Opportunities for Stewardship Interventions: A Single-Centre Cross-Sectional Study. *Antibiotics*. 2023;12(2):288. doi:10.3390/antibiotics12020288
76. DrugBank Online. Meropenem (DB00720) [Internet]. 2024 (2026 Jan 30). Available from: <https://go.drugbank.com/drugs/DB00720>
77. Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludwig K. Efficacy of Meropenem Monotherapy versus Combination Therapy with Meropenem and Moxifloxacin in Severe Sepsis: A Randomized Controlled Trial. *Clin Infect Dis*. 2012;55(10):1241–9. doi:10.1093/cid/cis165
78. Sjövall F, Perner A, Hylander Møller M. Empirical Mono- versus Combination Antibiotic Therapy in Adult Intensive Care Patients with Severe Sepsis – A Systematic Review with Meta-Analysis and Trial Sequential Analysis. *J Infect*. 2017;74(4):331–44. doi:10.1016/j.jinf.2016.11.013

79. Martínez ML, Plata-Menchaca EP, Ruiz-Rodríguez JC, Ferrer R. An approach to antibiotic treatment in patients with sepsis. *J Thorac Dis.* 2020;12(3):1007–21. doi:10.21037/jtd.2020.01.47
80. Ota K, Kaku N, Yanagihara K. Efficacy of Meropenem and Amikacin Combination Therapy Against Carbapenemase-Producing *Klebsiella pneumoniae* Mouse Model of Pneumonia. *J Infect Chemother.* 2020;26(12):1237–43. doi:10.1016/j.jiac.2020.07.002
81. Reinhardt JF, Johnston L, Ruane P, Johnson CC, Ingram-drake L, MacDonald K, et al. A randomized, double-blind comparison of sulbactam/ampicillin and clindamycin for the treatment of aerobic and aerobic-anaerobic infections. *Clin Infect Dis.* 1986;8(5):S569–75. doi:10.1093/clinids/8.Supplement_5.S569
82. Tamma PD, Cosgrove SE, Maragakis LL. Combination Therapy for Treatment of Infections with Gram-Negative Bacteria. *Clin Microbiol Rev.* 2012;25(3):450–70. doi:10.1128/CMR.05041-11
83. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of Hypotension Before Initiation of Effective Antimicrobial Therapy is The Critical Determinant of Survival in Human Septic Shock. *Crit Care Med.* 2006;34(6):1589–96. doi:10.1097/01.CCM.0000217961.75225.E9
84. Busch LM, Kadri SS. Antimicrobial Treatment Duration in Sepsis and Serious Infections. *J Infect Dis.* 2020;222(2):142–55. doi:10.1093/infdis/jiaa247
85. Takahashi N, Imaeda T, Nakada T, Oami T, Abe T, Yamao Y, et al. Short- versus Long-Course Antibiotic Therapy for Sepsis: A Post Hoc Analysis of The Nationwide Cohort Study. *J Intensive Care.* 2022;10(1):49. doi:10.1186/s40560-022-00642-3
86. Kubo K, Kondo Y, Yoshimura J, Kikutani K, Shime N. Short- versus prolonged-course antibiotic therapy for sepsis or infectious diseases in critically ill adults: a systematic review and meta-analysis. *Infect Dis.* 2022;54(3):213–23. doi:10.1080/23744235.2021.2001046
87. Lee RA, Stripling JT, Spellberg B, Centor RM. Short-Course Antibiotics for Common Infections: What Do We Know and Where Do We Go From Here? *Clin Microbiol Infect.* 2023;29(2):150–9. doi:10.1016/j.cmi.2022.08.024
88. Tansarli GS, Mylonakis E. Systematic Review and Meta-analysis of the Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults. *Antimicrob Agents Chemother.* 2018;62(9):1–13. doi:10.1128/AAC.00635-18

89. Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. *The Lancet*. 2017;390(10104):1770–80. doi:10.1016/S0140-6736(17)31002-4
90. Dipiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey LM. Pediatrics: Neonatal Critical Care. In: Dipiro's Pharmacotherapy: A Pathophysiologic Approach. 12th ed. United States: McGraw-Hill Company; 2023. 1–17 p.
91. Rumah Sakit Universitas Andalas. Panduan Praktik Klinis Rumah Sakit Syok Sepsis. Padang: Rumah Sakit Universitas Andalas; 2022.
92. Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). *Clin Microbiol Infect*. 2022;28(4):521–47. doi:10.1016/j.cmi.2021.11.025
93. Micek ST, Welch EC, Khan J, Pervez M, Doherty JA, Reichley RM, et al. Empiric Combination Antibiotic Therapy Is Associated with Improved Outcome against Sepsis Due to Gram-Negative Bacteria: a Retrospective Analysis. *Antimicrob Agents Chemother*. 2010;54(5):1742–8. doi:10.1128/AAC.01365-09
94. Tabah A, Bassetti M, Kollef MH, Zahar JR, Paiva JA, Timsit JF, et al. Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). *Intensive Care Med*. 2020;46(2):245–65. doi:10.1007/s00134-019-05866-w
95. Schwarzenbacher J, Kuhn SO, Vollmer M, Scheer C, Fuchs C, Rehberg S, et al. On-site blood culture incubation shortens the time to knowledge of positivity and microbiological results in septic patients. *PLOS ONE*. 2019;14(12):1–13. doi:10.1371/journal.pone.0225999
96. Burnham CAD, Yarbrough ML. Best Practices for Detection of Bloodstream Infection. *J Appl Lab Med*. 2019;3(4):740–2. doi:10.1373/jalm.2018.026260
97. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, Van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β -lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and *Pseudomonas aeruginosa* with Difficult-to-Treat Resistance (DTR-P. *aeruginosa*). *Clin Infect Dis*. 2022;75(2):187–212. doi:10.1093/cid/ciac268

98. Schuts EC, Hulscher MEJL, Mouton JW, Verduin CM, Stuart JWTC, Overdiek HWPM, et al. Current Evidence on Hospital Antimicrobial Stewardship Objectives: a Systematic Review and Meta-analysis. *Lancet Infect Dis.* 2016;16(7):847–56. doi:10.1016/S1473-3099(16)00065-7
99. Zilahi G, McMahon MA, Povoia P, Martin-Loeches I. Duration of antibiotic therapy in the intensive care unit. *J Thorac Dis.* 2016;8(12):3774–80. doi:10.21037/jtd.2016.12.89
100. Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database Syst Rev.* 2017;2(2):1–326. doi:10.1002/14651858.CD003543.pub4

